The US Court of Appeals for the Third Circuit concludes that the Actavis ruling applies to non-cash payments (Lamictal)

On June 26, 2015, in the first federal appellate drug patent settlement ruling since the Supreme Court’s decision in FTC v. Actavis, 133 S. Ct. 2223 (2013), the U.S. Court of Appeals for the Third Circuit overturned a lower court decision granting a motion to dismiss for defendants. Writing for a unanimous panel, Judge Anthony Scirica unequivocally found that Actavis applied to not only cash payments but also other forms of consideration including brand-firm promises not to introduce “authorized generics” that would compete with true generics. Background The case involves Lamictal, a drug that treats epilepsy and bipolar disorder. King Drug Co. of Florence v. Smithkline Beechham Corp., 791 F.3d 388, 396 (3d Cir. 2015). GlaxoSmithKline (GSK) obtained a patent, expiring in 2008, that

Access to this article is restricted to subscribers

Already Subscribed? Sign-in

Access to this article is restricted to subscribers.

Read one article for free

Sign-up to read this article for free and discover our services.

 

PDF Version

Author

  • Rutgers University (New Jersey)

Quotation

Michael A. Carrier, The US Court of Appeals for the Third Circuit concludes that the Actavis ruling applies to non-cash payments (Lamictal), 26 June 2015, e-Competitions Bulletin Competition in the Pharmaceutical sector, Art. N° 75208

Visites 317

All issues

  • Latest News issue 
  • All News issues
  • Latest Special issue 
  • All Special issues